Big Pharma's Pricing Power Imperiled By Part D Overhaul
Drugmakers will lose major leverage with private insurers in their pricing of products supplied through Medicare Part D if federal regulators follow through on new plans to eliminate mandatory coverage requirements,...To view the full article, register now.
Already a subscriber? Click here to view full article